**Aims and objectives of this session**

Invasion and metastasis in prostate cancer are regulated by different signaling molecules. In this session, the pathway of Wnt/beta-catenin and its interaction with other signaling cascades in prostate tumorigenesis and progression will be highlighted. In addition, novel findings about regulation of the key transcription factor ERG will be presented.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
growth factor dependent, intratumoral cell fate and behavior
By: Lu Q.1, Li M-C.1, Zhang J.2, Chen Y-H.2, Boykins C.1, Du J.3, Ai X.5, Chen B-A.6, Jiang Y-G.4
Institutes: 1Brody School Of Medicine At East Carolina University, Dept. of Anatomy and Cell Biology, Greenville, United States of America, 2Brody School Of Medicine At East Carolina University, Dept. of Anatomy And Cell Biology, Greenville, United States of America, 3Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing An Zhen Hospital, Capital Medical University, Beijing, China, 4Beijing An Zhen Hospital, Capital Medical University, Dept. of Urology, Beijing, China, 5PLA Army General Hospital, Dept. of Urology, Beijing, China, 6Southeast University School of Clinical Medicine, Dept. of Hematology and Oncology, Nanjing, China

Expression of checkpoint receptors in tumor-infiltrated T-cells of renal cell and prostate carcinomas
By: Bedke J.1, Zelba H.2, Hennenlotter J.1, Zettl M.3, Rammensee H-G.2, Stenzl A.1, Gouttefangeas C.2
Institutes: 1University of Tübingen, Dept. of Urology, Tübingen, Germany, 2University of Tübingen, Dept. of Immunology, Tübingen, Germany, 3Boehringer Ingelheim RCV GmgH & CoKG, NBE Discovery, Vienna, Austria

Evaluation of systematic alterations in the proteome by androgen receptor stimulation and blockade in prostate cancer
By: Molokwu C.1, Kristensen A.2, Zhang F.3, Saxena N.3, Shrestha R.4, Bell R.4, Hach F.4, Collins C.5, Sorensen P.6, Gleave M.5
Institutes: 1Bradford Royal Infirmary, Dept. of Urology, Bradford, United Kingdom, 2British Columbia Cancer Research Centre, Proteomics Unit, Vancouver, Canada, 3Vancouver Prostate Centre, Tumour Biology Group, Vancouver, Canada, 4Vancouver Prostate Centre, Bioinformatics Group, Vancouver, Canada, 5University of British Columbia, Dept. of Urological Sciences, Vancouver, Canada, 6University of British Columbia, Dept. of Pathology & Laboratory Medicine, Vancouver, Canada

Description of the dimerization surface for the ligand-binding domain of the androgen receptor and its role in transcriptional control by agonists and antagonists
By: Claessens F.1, Nadal M.2, Prekovic S.1, Gallastegui N.3, Helsen C.1, Abella M.2, Zielinska K.2, Gay M.3, Vilaseca M.3, Taules M.4, Houtsueller A.5, Van Royen M.6, Fuentes-Prior P.7, Estebanez-Perpina E.2
Institutes: 1KU Leuven, Molecular Endocrinology Laboratory, Leuven, Belgium, 2Institute of Biomedicine of The University of Barcelona, Dept. of Biochemistry and Molecular Biomedicine, Barcelona, Spain, 3Parc Cientific De Barcelona, Mass Spectrometry Core Facility, Barcelona, Spain, 4Centres Cientifics I Tecnologics, Unitat De Citometra, Barcelona, Spain, 5Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands

Bone morphogenic protein-6 and retinoblastoma expression: An inverse relationship in prostate cancer progression?
By: McCormick K.1, Leiblich A.1, Stevens D.1, Alves C.1, Fan S-J.1, Carr K.1, Morris J.1, Harris A.2, Wilson C.1, Hamdy F.3, Goberdhan D.1
Institutes: 1University of Oxford, Dept. of Physiology, Anatomy and Genetics, Oxford, United Kingdom, 2University of Oxford, The Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom, 3University of Oxford, Nuffield Department of Surgical Sciences, John Radcliffe Hospital, Oxford, United Kingdom

Epigenetics in prostate cancer
G. Jenster, Rotterdam (NL)